Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07396168 · ClinicalTrials.gov registry record · Phase 4
Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.
A Phase 4 study of Lichen Plano-Pilaris, sponsored by The Skin Center Dermatology Group.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT07396168: Recruiting Phase 4 study of Lichen Plano-Pilaris, sponsored by The Skin Center Dermatology Group.
NCT07396168 is a Phase 4 study of Lichen Plano-Pilaris that is actively recruiting participants, run by The Skin Center Dermatology Group. The registered enrollment target is 10 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07396168, a Phase 4 study of Lichen Plano-Pilaris, is actively recruiting participants, sponsored by The Skin Center Dermatology Group.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Lichen planopilaris (LPP) is a primary lymphocytic cicatricial alopecia characterized by progressive, permanent hair loss and scalp symptoms such as pruritus and burning. Current treatments-including topical and intralesional corticosteroids, hydroxychloroquine, and immunosuppressants-are often inadequate, with limited evidence for efficacy and frequent treatment switching or discontinuation due to side effects or lack of response.1,2 Recent systematic reviews and meta-analyses highlight the need for new, targeted therapies. 3,4 Nemolizumab, an IL-31 receptor antagonist, FDA-approved for prurigo nodularis and atopic dermatitis, has demonstrated efficacy in pruritic and fibrosing dermatoses, making it a rational candidate for LPP.
Conditions Studied
Interventions
- DRUG Nemolizumab
Study Locations (1)
New York
- The Skin Center Dermatology Group - New City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2027-06 |
| Phase | Phase 4 |
What NCT07396168 shows while recruiting
NCT07396168 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Lichen Plano-Pilaris appearing as the primary indexed condition, and to 1 intervention - of which Nemolizumab is the first listed.
NCT07396168 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07396168 about?
NCT07396168 is a clinical study titled "Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.". Lichen planopilaris (LPP) is a primary lymphocytic cicatricial alopecia characterized by progressive, permanent hair loss and scalp symptoms such as pruritus and burning. Current treatments-including topical and intralesional corticosteroids, hydroxychloroquine, and immunosuppressants-are often inad...
What is the current status of trial NCT07396168?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2026-02-01. Estimated completion is 2027-06.
What conditions does trial NCT07396168 study?
This clinical trial studies the following conditions: Lichen Plano-Pilaris.
What interventions are being tested in trial NCT07396168?
The interventions under investigation include: Nemolizumab (DRUG).
Who is sponsoring clinical trial NCT07396168?
This trial is sponsored by The Skin Center Dermatology Group, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07396168 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lichen Plano-Pilaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07396168's enrollment target sits among peer trials
10 1941st of 2000 higher than 33 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI